Loma Linda University

Enrollment Information
Call us at: 909-558-1000

Faculty Directory
  
Christopher Morris, MD
Professor, Pediatrics
School of Medicine
Presentations    Research Presentations -- National
  • Chris Morris. "Treatment of regimen related toxicity following bone marrow transplant with antithrombin III." American society of hematology. Seattle WA ( 12/1995 )
  Presentations given to non-academic audiences
  • Christopher Morris. "Multiple Myeloma Update 2004." Medical Oncology Grand Rounds. Loma Linda University Hospital ( 12/2004 )
  • Christopher Morris. "Febrile Neutropenia." Company sponsored symposia. Eisenhower Memorial Hospital Rancho Mirage CA ( 11/2003 )
  • Chris Morris. "Influence of busulfan pharmacokinetics on transplant toxicity." Invited lecture. Loyola University Chacago Cancer Center, Chicago IL ( 2/2001 )
  • Chris Morris. "Stem cell mobilization in patients > 70 years with multiple myeloma." American Society of Hematology. SanFrancisco CA ( 12/2000 )
  • Chris Morris. "Antithrombin III prophylaxis for regimen related toxicity in BMT patients." Invited lecture. Genzyme Corporation, Boston MA ( 12/2000 )
  • Chris Morris. "Role of antithrombin III in transplant regimen related toxicity." Midwest Stem Cell Transplant Symposia. Cincinnati OH ( 6/1998 )
  • Chris Morris. "Treatment of Regimen Related Toxicity with antithrombin III in BMT patients." Invited lecture. University of Wisconsin adult marrow transplant division, Madison WI ( 12/1996 )
  • Chris Morris. "Comparison of engraftment and GVHD following transplantation with elutriated HLA-compatible unrelated donor bone marrow or umbilical cord blood." American Society of Hematology. Orlando FL ( 12/1996 )
  • Chris Morris. "Prophylaxtic continuous infusion antithrombin III for prevention of regimen related toxicity following bone marrow transplantation." American Society of Hematology. Orlando FL ( 12/1996 )
  • Chris Morris. "Treatment and prevention of regimen related toxicity with antithrombin III in BMT patients." Invited lecture. University of Minnesota, Mayo Memorial Hospital ( 12/1996 )
  • Chris Morris. "Treatment and prevention of regimen related toxicity with antithrombin III in BMT patients." Invited lecture. University of Indiana, Riley Children's Hospital ( 7/1996 )
  • Chris Morris. "Adhesion among sickle cells correlates with disease severity." American Society of Hematology. Nashville TN ( 12/1994 )
  • M Kumar, Chris Morris. "Bone marrow transplantation in Fanconi Anemia with non-sibling donors or following leukemic transformation." American Society of Hematology. Anaheim CA ( 12/1992 )
  • M Kumar and Chris Morris. "Bone marrow transplantation in Fanconi Anemia." American Society of Hematology. Anaheim CA ( 12/1992 )
  • Chris Morris. "Deoxygenation-induced changes in sickle blood yield stress." American Society of Hematology. Denver CO ( 12/1991 )
  • Chris Morris. "Deoxygenation induced changes in sickle cell adnerence." Annual Meeting of the National Sickle Cell Centers. Mobile AL ( 3/1991 )
  • Christopher and Joan Morris. "An Introduction to Blood and Marrow Transplant." Pediatric Grand Rounds. Loma Linda Children's Hospital (*)
  • Chris Morris. "Update on Multiple Myeloma 2002." Medicine Ground Rounds. VA Medical Center Loma Linda (*)
  • Christopher Morris. "Acute Lymphoblastic Leukemia. A clinical update." Company sponsored symposia. Celgene, San Diego CA (*)
  • Chris Morris. "Influence of busulfan pharmacokinetics on transplant toxicity." Invited lecture. Strong Memorial Hospital, University of Rochester, New York (*)